TG Therapeutics Says FDA Confirmed That Accelerated Approval Based On Overall Response Rate Would Be A Review Issue, Also Discussed Potential Use Of Progression Free Survial From GENUINE Trial To Support Full Approval of TG-1101
Paul Quintaro